Details about Mark Sculpher

Access statistics for papers by Mark Sculpher.

Last updated 2023-03-11. Update your information in the RePEc Author Service.

Short-id: psc810

Working Papers

2017

1. Scoping review on social care economic evaluation methods
   Working Papers, Centre for Health Economics, University of York

2016

2. Supporting the development of an essential health package: principles and initial assessment for Malawi
   Working Papers, Centre for Health Economics, University of York View citations (3)

2015

3. Country-level cost-effectiveness thresholds: initial estimates and the need for further research
   Working Papers, Centre for Health Economics, University of York View citations (44)

2014

4. Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?
   Working Papers, Centre for Health Economics, University of York View citations (10)

2013

5. Methods for the estimation of the NICE cost effectiveness threshold
   Working Papers, Centre for Health Economics, University of York View citations (49)

2012

6. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions
   Working Papers, Centre for Health Economics, University of York View citations (25)

2011

7. Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS
   Working Papers, Centre for Health Economics, University of York View citations (12)

2010

8. Appropriate Perspectives for Health Care Decisions
   Working Papers, Centre for Health Economics, University of York View citations (48)

2007

9. Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions
   Working Papers, Centre for Health Economics, University of York View citations (14)

2006

10. Defining and characterising structural uncertainty in decision analytic models
    Working Papers, Centre for Health Economics, University of York View citations (6)

2005

11. The value of implementation and the value of information: combined and uneven development
    Working Papers, Centre for Health Economics, University of York View citations (3)

2000

12. Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling
    Working Papers, Centre for Health Economics, University of York View citations (11)

1999

13. A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis
    Working Papers, Centre for Health Economics, University of York View citations (1)
14. Building Uncertainty into Cost-Effectiveness Rankings: Portfolio Risk-Return Trade-Offs and Implications for Decision Rules
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada
15. Income Effects of Reduced Health and Health Effects of Reduced Income: Implications for Health State Valuation
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada
16. Recognizing Preference Diversity: The Use of Preference Sub-Groups in Cost-Effectiveness Analysis
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada

1996

17. Antenatal testing for HIV Infection: Developing a Model for Economic Evaluation
    Discussion Papers, Brunel University, Health Economics Research Group

1995

18. Economic Evaluation in Health Care Research and Development: Undertake it Early and Often
    Discussion Papers, Brunel University, Health Economics Research Group View citations (2)

Journal Articles

2018

1. How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework
   Health Economics, 2018, 27, (2), e41-e54 View citations (1)
2. Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system
   Health Economics, 2018, 27, (2), e28-e40

2016

3. Should the Lambda (λ) Remain Silent?
   PharmacoEconomics, 2016, 34, (4), 323-329

2015

4. CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
   Health Economics, 2015, 24, (1), 1-7 View citations (25)

2014

5. What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer
   Applied Health Economics and Health Policy, 2014, 12, (5), 497-510

2013

6. Acknowledging Patient Heterogeneity in Economic Evaluation
   PharmacoEconomics, 2013, 31, (2), 111-123 View citations (2)

2012

7. Golimumab for the Treatment of Psoriatic Arthritis
   PharmacoEconomics, 2012, 30, (4), 257-270 View citations (23)
8. Real Economics Needs to Reflect Real Decisions
   PharmacoEconomics, 2012, 30, (2), 133-136 View citations (3)

2011

9. Dangerous omissions: the consequences of ignoring decision uncertainty
   Health Economics, 2011, 20, (2), 212-224 View citations (13)

2010

10. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?
    The European Journal of Health Economics, 2010, 11, (1), 57-66
11. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods
    Health Economics, 2010, 19, (10), 1132-1136 View citations (3)

2009

12. Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations
    Health Policy, 2009, 93, (2-3), 85-92 View citations (29)

2007

13. A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
    PharmacoEconomics, 2007, 25, (10), 829-841
14. Recombinant Erythropoietin for Chemotherapy-Related Anaemia
    PharmacoEconomics, 2007, 25, (3), 223-237 View citations (3)

2006

15. Assessing Generalisability in Model-Based Economic Evaluation Studies
    PharmacoEconomics, 2006, 24, (12), 1181-1197 View citations (3)
16. Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion
    Health Economics, 2006, 15, (1), 1-4 View citations (18)
17. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis
    Health Economics, 2006, 15, (4), 373-381 View citations (12)
18. Whither trial‐based economic evaluation for health care decision making?
    Health Economics, 2006, 15, (7), 677-687 View citations (44)

2005

19. Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models
    Health Economics, 2005, 14, (5), 471-485 View citations (22)
20. Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility
    Health Economics, 2005, 14, (5), 487-496 View citations (28)
21. Estimating utility data from clinical indicators for patients with stable angina
    The European Journal of Health Economics, 2005, 6, (4), 347-353 View citations (7)
22. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
    Health Economics, 2005, 14, (4), 339-347 View citations (73)

2002

23. Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply
    Health Economics, 2002, 11, (7), 653-654
24. Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions
    Social Science & Medicine, 2002, 54, (9), 1369-1377 View citations (5)

2001

25. Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis
    Health Economics, 2001, 10, (4), 317-324 View citations (15)
26. Representing uncertainty: the role of cost‐effectiveness acceptability curves
    Health Economics, 2001, 10, (8), 779-787 View citations (80)

2000

27. Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy
    PharmacoEconomics, 2000, 17, (4), 361-370 View citations (1)

1998

28. The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia
    Health Economics, 1998, 7, (2), 129-142 View citations (2)

1995

29. Sensitivity analysis in economic evaluation: A review of published studies
    Health Economics, 1995, 4, (5), 355-371 View citations (13)

Books

2006

1. Decision Modelling for Health Economic Evaluation
   OUP Catalogue, Oxford University Press View citations (391)

Chapters

2012

1. Decision-making with Uncertainty: The Value of Information
   Chapter 51 in The Elgar Companion to Health Economics, Second Edition, 2012
   Also in Chapter 48 in The Elgar Companion to Health Economics, 2006 (2006)